Incidence and risk factors of pneumococcal pneumonia in adults: a population-based study.

Olga Ochoa-Gondar, Ver��nica Torras-Vives, Cinta de Diego-Cabanes, Eva M Satu��-Gracia, Angel Vila-Rovira, Mar��a J Forcadell-Perisa, Domingo Ribas-Segu��, Clara Rodr��guez-Casado, Angel Vila-C��rcoles
Author Information
  1. Olga Ochoa-Gondar: Primary Health Care Service "Camp de Tarragona", Institut Catal�� de la Salut, Tarragona, Spain.
  2. Ver��nica Torras-Vives: Primary Health Care Service "Camp de Tarragona", Institut Catal�� de la Salut, Tarragona, Spain.
  3. Cinta de Diego-Cabanes: Primary Health Care Service "Camp de Tarragona", Institut Catal�� de la Salut, Tarragona, Spain. mcdiego.tgn.ics@gencat.cat.
  4. Eva M Satu��-Gracia: Primary Health Care Service "Camp de Tarragona", Institut Catal�� de la Salut, Tarragona, Spain.
  5. Angel Vila-Rovira: Primary Health Care Service "Camp de Tarragona", Institut Catal�� de la Salut, Tarragona, Spain.
  6. Mar��a J Forcadell-Perisa: Primary Health Care Service "Camp de Tarragona", Institut Catal�� de la Salut, Tarragona, Spain.
  7. Domingo Ribas-Segu��: Primary Health Care Service "Camp de Tarragona", Institut Catal�� de la Salut, Tarragona, Spain.
  8. Clara Rodr��guez-Casado: Information System for the Improvement of Research in Primary Care (SIDIAP), Primary Care Research Institute Jordi Gol, Universitat Autonoma de Barcelona, Barcelona, Spain.
  9. Angel Vila-C��rcoles: Primary Health Care Service "Camp de Tarragona", Institut Catal�� de la Salut, Tarragona, Spain.

Abstract

BACKGROUND: Infection caused by Streptococcus pneumoniae, mainly invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP), are a major public health problem worldwide. This study investigated population-based incidence and risk of PP among Catalonian persons���������50 years-old with and without specific underlying conditions/comorbidities, examining the influence of single and multi-comorbidities in the risk of suffering PP.
METHODS: Population-based cohort study involving 2,059,645 persons���������50 years-old in Catalonia, Spain, who were retrospectively followed between 01/01/2017-31/12/2018. The Catalonian information system for development of research in primary care (SIDIAP) was used to establish baseline characteristics of the cohort (comorbidities/underlying conditions), and PP cases were collected from discharge codes (ICD-10: J13) of the 68 referral Catalonian hospitals.
RESULTS: Global incidence rate (IR) was 90.7 PP cases per 100,000 person-years, with a 7.6% (272/3592) case-fatality rate (CFR). Maximum IRs emerged among persons with history of previous IPD or all-cause pneumonia, followed by haematological neoplasia (475.0), HIV-infection (423.7), renal disease (384.9), chronic respiratory disease (314.7), liver disease (232.5), heart disease (221.4), alcoholism (204.8), solid cancer (186.2) and diabetes (159.6). IRs were 42.1, 89.9, 201.1, 350.9, 594.3 and 761.2 in persons with 0, 1, 2, 3, 4 and ������5 comorbidities, respectively. In multivariable analyses, HIV-infection (hazard ratio [HR]: 5.16; 95% CI: 3.57-7.46), prior all-cause pneumonia (HR: 3.96; 95% CI: 3.45-4.55), haematological neoplasia (HR: 2.71; 95% CI: 2.06-3.57), chronic respiratory disease (HR: 2.66; 95% CI: 2.47-2.86) and prior IPD (HR: 2.56; 95% CI: 2.03-3.24) were major predictors for PP.
CONCLUSION: Apart of increasing age and immunocompromising conditions (classically recognised as high-risk conditions), history of prior IPD/pneumonia, presence of chronic pulmonary/respiratory disease and/or co-existing multi-comorbidity (i.e., two or more underlying conditions) are major risk factors for PP in adults, with an excess risk near to immunocompromised subjects. Redefining risk categories for PP, including all the above-mentioned conditions into the high-risk category, could be necessary to improve prevention strategies in middle-aged and older adults.

Keywords

References

  1. Clin Infect Dis. 2021 Oct 5;73(7):e1489-e1497 [PMID: 32716500]
  2. Vaccine. 2019 Jan 7;37(2):226-234 [PMID: 30527660]
  3. Expert Rev Vaccines. 2021 Mar;20(3):243-256 [PMID: 33478306]
  4. Pharmacoeconomics. 2019 Sep;37(9):1093-1127 [PMID: 31025189]
  5. Vaccine X. 2023 Jan 21;13:100264 [PMID: 36798107]
  6. Respir Med. 2018 Apr;137:6-13 [PMID: 29605214]
  7. Clin Infect Dis. 2017 Oct 30;65(10):1736-1744 [PMID: 29028977]
  8. Lung. 2020 Jun;198(3):481-489 [PMID: 32253492]
  9. BMC Infect Dis. 2008 Jul 22;8:96 [PMID: 18647385]
  10. Am J Epidemiol. 1999 Feb 1;149(3):282-9 [PMID: 9927225]
  11. Pathogens. 2020 Apr 03;9(4): [PMID: 32260132]
  12. J Infect Dis. 2005 Aug 1;192(3):377-86 [PMID: 15995950]
  13. Eur J Clin Microbiol Infect Dis. 2019 Apr;38(4):785-791 [PMID: 30778705]
  14. Semin Respir Crit Care Med. 2005 Dec;26(6):563-74 [PMID: 16388428]
  15. PLoS One. 2013;8(4):e60273 [PMID: 23565216]
  16. Int J Infect Dis. 2015 Aug;37:30-5 [PMID: 25997673]
  17. Hum Vaccin Immunother. 2021 Oct 3;17(10):3670-3686 [PMID: 34106040]
  18. BMC Infect Dis. 2018 Apr 27;18(1):196 [PMID: 29699550]
  19. Expert Rev Vaccines. 2020 Dec;19(12):1141-1151 [PMID: 33428494]
  20. Vaccine. 1999 Jul 30;17 Suppl 1:S11-8 [PMID: 10471174]
  21. Inform Prim Care. 2011;19(3):135-45 [PMID: 22688222]
  22. Med Clin (Barc). 2013 Mar 2;140(5):223.e1-223.e19 [PMID: 23276610]

Grants

  1. code file PI20/01223/This work was supported by a grant from the "Fondo de Investigaci��n Sanitaria" of the "Instituto de Salud Carlos III" (call 2020) for the "Acci��n Estrat��gica en Salud 2020/2030 (code file PI20/01223), cofinanced by the European Union through the "Fondo Europeo de Desarrollo Regional" (FEDER).

MeSH Term

Middle Aged
Humans
Aged
Pneumonia, Pneumococcal
Incidence
Cohort Studies
Retrospective Studies
Risk Factors
Pneumococcal Infections
Neoplasms
Pneumococcal Vaccines

Chemicals

Pneumococcal Vaccines

Word Cloud

Created with Highcharts 10.0.02PPdiseaseriskpneumoniaconditions395%CI:7HR:pneumococcalIPDmajorstudyCatalonian9chronic1priorfactorspopulation-basedincidenceamongpersons���������50years-oldunderlyingcohortfollowedcasesrateIRspersonshistoryall-causehaematologicalneoplasia0HIV-infectionrespiratory54high-riskadultsIncidenceBACKGROUND:InfectioncausedStreptococcuspneumoniaemainlyinvasivepublichealthproblemworldwideinvestigatedwithoutspecificconditions/comorbiditiesexamininginfluencesinglemulti-comorbiditiessufferingMETHODS:Population-basedinvolving059645CataloniaSpainretrospectively01/01/2017-31/12/2018informationsystemdevelopmentresearchprimarycareSIDIAPusedestablishbaselinecharacteristicscomorbidities/underlyingcollecteddischargecodesICD-10:J1368referralhospitalsRESULTS:GlobalIR90per100000person-years6%272/3592case-fatalityCFRMaximumemergedprevious475423renal384314liver232heart221alcoholism2048solidcancer186diabetes15964289201350594761������5comorbiditiesrespectivelymultivariableanalyseshazardratio[HR]:1657-7469645-4557106-3576647-2865603-324predictorsCONCLUSION:ApartincreasingageimmunocompromisingclassicallyrecognisedIPD/pneumoniapresencepulmonary/respiratoryand/orco-existingmulti-comorbidityietwoexcessnearimmunocompromisedsubjectsRedefiningcategoriesincludingabove-mentionedcategorynecessaryimprovepreventionstrategiesmiddle-agedolderadults:AdultsMultimorbidityPneumococcalRisk

Similar Articles

Cited By